cdn mobile

DOH Usec addressed Dengvaxia concerns during Cebu visit

By: Futch Anthony Inso, Norman V. Mendoza February 02,2018 - 08:00 PM

Department of Health (DOH) Undersecretary Herminigildo Valle visited residents of the cities of Lapu-Lapu and Talisay, Cebu yesterday to answer queries from parents regarding the department’s dengue vaccination program.

Valle assures the public that the government will address concerns on children who were vaccinated with Dengvaxia.

“Just tell us your concerns, and we’ve already put up a mechanism for children who will get infected with dengue and has already acquired Dengvaxia,” Valle said.

More than 160,000 children, with ages ranging from 9 to 14 years old, were vaccinated last year in Cebu.

Last December 2017, Sanofi Pastuer, the manufacturer of Dengvaxia, announced that children who received the vaccine may experience severe dengue, particularly for those children who have never been infected by the virus.

Valle said that parents may bring their children to the nearest public hospitals to get free medical assistance.

However, they may need to pay a portion of the hospital bill if the patient will be brought to a private hospital.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Read Next

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

TAGS: concerns, Dengvaxia, DOH, during
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.